EcoDrugPlus

Peroxisome Proliferator-Activated Receptor Alpha A

Ensembl ID : ENSLOCG00000017030
Gene Symbol: PPARAA
1 Cross references
454 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Delta-Like

Ensembl ID : ENSLOCG00000011628
Gene Symbol: LOC102683645
3 Cross references
418 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSLOCG00000001119
Gene Symbol: PIK3CA
3 Cross references
210 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSLOCG00000004421
Gene Symbol: PIK3CB
3 Cross references
216 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSLOCG00000015829
Gene Symbol: PIK3CG
3 Cross references
213 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Delta

Ensembl ID : ENSLOCG00000006919
Gene Symbol: PIK3CD
1 Cross references
213 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSLOCG00000016520
Gene Symbol: PDE10A
3 Cross references
205 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSLOCG00000015415
Gene Symbol: PDE3A
1 Cross references
272 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSLOCG00000003151
Gene Symbol: PDE3B
3 Cross references
217 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSLOCG00000007575
Gene Symbol: PDE4A
1 Cross references
266 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSLOCG00000006922
Gene Symbol: PDE4B
3 Cross references
301 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSLOCG00000007665
Gene Symbol: PDE4D
3 Cross references
244 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).